ArticleAlzheimer's & dementia (New York, N. Y.)2015
Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change?
Article in Alzheimer's & dementia (New York, N. Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial.Nature medicine · 2026Trial
- Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer's disease.Nature aging · 2026Trial
- Risk of a Dementia Diagnosis in Community-Dwelling Older Adults With Normal MMSE Scores in the United States.American journal of medicine open · 2026Article
- Limited Diagnostic Performance of Cerebrospinal Fluid Glial Fibrillary Acidic Protein in Dementia.Dementia and geriatric cognitive disorders · 2026Article
- Investigating the potential clinical impact of periodontitis on the progression of Alzheimer's disease: a prospective cohort study.Clinical oral investigations · 2023Article
- Handgrip strength but not SARC-F score predicts cognitive impairment in older adults with multimorbidity in primary care: a cohort study.BMC geriatrics · 2022Article
- Influence of Subject-Specific Effects in Longitudinal Modelling of Cognitive Decline in Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2022Article
- Cognitive Function Characterization Using Electronic Health Records Notes.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2021Article
- Distinguishing Frontotemporal Dementia From Alzheimer Disease Through Everyday Function Profiles: Trajectories of Change.Journal of geriatric psychiatry and neurology · 2021Article
- Prognostic value of a rapid sarcopenia measure in acutely ill older adults.Clinical nutrition (Edinburgh, Scotland) · 2020Article
- Progression of Alzheimer's Disease by Self-Reported Cancer History in the Alzheimer's Disease Neuroimaging Initiative.Journal of Alzheimer's disease : JAD · 2020Observational
- Using practice effects for targeted trials or sub-group analysis in Alzheimer's disease: How practice effects predict change over time.PloS one · 2020Article
- Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.) · 2019Article
- Analyses of natural courses of Japanese patients with Alzheimer's disease using placebo data from placebo-controlled, randomized clinical trials: Japanese Study on the Estimation of Clinical course of Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.) · 2019Article
- A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease.Statistics in medicine · 2018Observational
- A similarity-based approach to leverage multi-cohort medical data on the diagnosis and prognosis of Alzheimer's disease.GigaScience · 2018Article
- Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative.Neuro-degenerative diseases · 2018Article
- Therapeutic time window of disease-modifying therapy for early Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPost hoc analyses from clinical trials in Alzheimer's disease suggest more cognitively impaired participants respond differently from less impaired on cognitive outcomes. We examined pooled clinical trials data to assess the utility of enriching trials using baseline cognition.
methodsWe included 2,882 participants with mild to moderate AD in 7 studies from a meta-database. We used mixed effects models to estimate rate of decline in ADAS-cog scores among MMSE groups.
findingsBaseline MMSE category was associated with baseline scores and rate of decline on the ADAS-cog, adjusting for age and education (both p<0.001). Greater baseline cognitive impairment was associated with more rapid progression. INTERPRETATIONS: Although we found significant differences in rate of decline, the majority of differences between individuals were from baseline ADAS-cog values. Enrichment based on MMSE would reduce the recruitment pool while adding only slightly to detecting differences in rate of progression and is not advised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.